The biological actions of lipopolysaccharides (LPSs) from Sinorhizobium meliloti, Mesorhizobium loti and Escherichia coli were compared. In biological activities including lethality, production of tumor necrosis factor (TNF)-α and nitric oxide (NO), adjuvant action and Limulus activity, LPS from S. meliloti exhibited stronger actions than LPS from M. loti, but had a weaker action than LPS from E. coli. On the other hand, M. loti LPS showed a higher activity to activate human complement than S. meliloti LPS. Further, there was a significant difference in polymyxin B binding between S. meliloti LPS and M. loti LPS, suggesting a difference in the lipid A structure. LPSs from S. meliloti and M. loti seem to exhibit characteristic biological actions that may be dependent on the difference in the lipid A structure.
Spaink HPRoot nodulation and infection factors produced by rhizobial bacteria. Annu Rev Microbiol2000; 54: 257—288.
2.
Denarie J., Debelle F., Prome JCRhizobium lipochitooligosaccharidenodulationfactors: signaling molecules mediating recognition and morphogenesis. Annu Rev Biochem1996; 65: 503—535.
3.
Loppnow H., Libby P., Freudenberg M., Krauss JH, Weckesser J., Mayer H.Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun1990; 58: 3743—3750.
4.
Urbanik-Sypniewska T., Choma A., Kutkowska J. et al. Cytokine inducing activities of rhizobial and mesorhizobial lipopolysaccharides of different lethal toxicity. Immunobiology2000; 202: 408—420.
5.
Westphal O., Jann K.Bacterial lipopolysaccharides-extraction with phenol water and further application of the procedure. Methods Carbohydr Chem1965 ; 5: 83—91.
6.
Yokochi T., Inoue Y., Yokoo J., Kimura Y., Kato N.Retention of bacterial lipopolysaccharide at the side of subcutaneous injection . Infect Immun1989; 57: 1786—1791.
7.
Hitchcock PJ , Brown TMMorphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol1983; 154: 269—277.
8.
Green LC, Wagner Dda, Glowgowski J., Skepper PL, Wishnok JS, Tannenbaum SRAnalysis of nitrate, nitrite and 15N nitrate in biological fluids. Anal Biochem1982; 126: 131—138.
9.
Yokochi T., Inoue Y., Kimura Y., Kato N.Strong interaction of lipopolysaccharides possessing the mannose homopolysaccharides with complement and its relation to adjuvant action. J Immunol1990; 144: 3106—3110.
10.
Morrison DC , Jacobs DMBinding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry1976; 13: 813—818.
11.
Jacobs DM, Morrison DCInhibition of the mitogenic response to lipopolysaccharide (LPS) in mouse spleen cells by polymyxin B. J Immunol1977 ; 118: 21—27.
12.
Peterson AA , Fesik SW, McGroarty EJDecreased binding of antibiotics to lipopolysaccharides from polymyxin-resistant strains of Escherichia coli and Salmonella typhimurium . Antimicrob Agents Chemother1987; 31: 230—237.
13.
Rana FR, Blazyk J.Interactions between the antimicrobial peptide, magainin 2, and Salmonella typhimurium lipopolysaccharides. FEBS Lett1991; 293: 11—15.
14.
Galanos C., Freudenberg MA, Katschinski T., Salomao R., Mossmann H., Kumazawa Y.Tumor necrosis factor and host response to endotoxin, In: Ryan JL, Morrison DC. (eds) Bacterial Endotoxic Lipopolysaccharides, Vol. 2. Boca Raton, FL: CRC Press, 1992; 75—104.
15.
Lehman V., Freudenberg MA, Galanos C.Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med1987; 163: 657—663.
16.
Freudenberg MA, Galanos C.Interaction of lipopolysaccharides and lipid A with complement in rats and its relation to endotoxicity. Infect Immun1978; 19: 875—882.
17.
Wilson ME, Morrison DCEvidence for different requirements in physical state for the interaction of lipopolysaccharides with the classical and alternative pathways of complement . Eur J Biochem1982; 128: 137—141.
18.
Vukajlovich SWAntibody-independentactivationofthe classical pathway of human serum complement by lipid A is restricted to re-chemotype lipopolysaccharide and purified lipid A. Infect Immun1986; 53: 480—485.
19.
Vukajlovich SW, Hoffman J., Morrison DCActivation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of the classical and alternative pathways. Mol Immunol1987; 24: 319—331.
20.
Jiang GZ, Sugiyama T., Kato Y., Koide N., Yokochi T.Binding of mannose-binding protein to Klebsiella O3 lipopolysaccharide possessing the mannose homopolysaccharide as the O-specific polysaccharide and its relation to complement activation. Infect Immun1995 ; 63: 2537—2540.
21.
Dierich MP, Bitter-Suermann D., Konig W., Hadding U., Galanos C., Rietschel ETAnalysis of bypass activation of C3 by endotoxicLPS and loss of this potency . Immunology1973; 24: 721—731.
22.
Galanos C., Luderitz O.The role of the physical state of lipopolysaccharides in the interaction with complement. High molecular weight as prerequisite for the expression of anti-complementary activity. Eur J Biochem1976; 65: 403—408.
23.
Morrison DC, Kline LFActivation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol1977; 118: 362—368.
24.
Price NP, Kelly TM, Raetz CR, Carlson RWBiosynthesis of a structurally novel lipid A in Rhizobium leguminosarum: identification and characterization of six metabolic steps leading from UDP-GlcNAc to 3-deoxy-D-manno-2-octulosonic acid2lipid IVA. J Bacteriol1994; 176: 4646—4655.
25.
Russa R., Urbanik-Sypniewska T., Lindstrom K., Mayer H.Chemical characterization of two lipopolysaccharide species isolated from Rhizobium loti NZP2213. Arch Microbiol1995 ; 163: 345—-351.
26.
Kannenberg EL, Carlson RWLipid A and O-chain modifications cause Rhizobium lipopolysaccharides to become hydrophobic during bacteroid development. Mol Microbiol2001; 39: 379—391.
27.
Bhat UR, Forsberg LS, Carlson RWStructure of lipid A component of Rhizobium leguminosarum bv. phaseoli lipopolysaccharide. Unique nonphosphorylatedlipid A containing 2-amino-2-deoxygluconate, galacturonate, and glucosamine. J Biol Chem1994; 269: 14402-14410.
28.
Schromm AB, Brandenburg K., Loppnow H. et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem2000; 267: 2008—2013.
29.
Schromm AB, Brandenburg K., Loppnow H. et al. The charge of endotoxin molecules influences their conformation and IL-6-inducing capacity. J Immunol1998 ; 161: 5464—5471.
30.
Pollack M., Ohl CAEndotoxin-based molecular strategies for the prevention and treatment of Gram-negative sepsis and septic shock: pathology of septic shock. Curr Top Microbiol Immunol1996; 216: 275—297.
31.
Heumann D., Glauser MPAnticytokine strategies for the treatment of septic shock: relevance of animal models. Curr Top Microbiol Immunol1996; 216: 299—309.
